166 related articles for article (PubMed ID: 37974213)
1. Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy.
Singh A; Pruett N; Dixit S; Gara SK; Wang H; Pahwa R; Schrump DS; Hoang CD
J Exp Clin Cancer Res; 2023 Nov; 42(1):304. PubMed ID: 37974213
[TBL] [Abstract][Full Text] [Related]
2. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
3. Effective inhibition of MYC-amplified group 3 medulloblastoma by FACT-targeted curaxin drug CBL0137.
Wang J; Sui Y; Li Q; Zhao Y; Dong X; Yang J; Liang Z; Han Y; Tang Y; Ma J
Cell Death Dis; 2020 Dec; 11(12):1029. PubMed ID: 33268769
[TBL] [Abstract][Full Text] [Related]
4. The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing
De S; Lindner DJ; Coleman CJ; Wildey G; Dowlati A; Stark GR
Cancer Res; 2018 May; 78(9):2396-2406. PubMed ID: 29440145
[TBL] [Abstract][Full Text] [Related]
5. Histone chaperone FACT complex inhibitor CBL0137 interferes with DNA damage repair and enhances sensitivity of medulloblastoma to chemotherapy and radiation.
Song H; Xi S; Chen Y; Pramanik S; Zeng J; Roychoudhury S; Harris H; Akbar A; Elhag SS; Coulter DW; Ray S; Bhakat KK
Cancer Lett; 2021 Nov; 520():201-212. PubMed ID: 34271103
[TBL] [Abstract][Full Text] [Related]
6. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG.
Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS
Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836
[TBL] [Abstract][Full Text] [Related]
7. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
8. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothened Antagonists.
Mo J; Liu F; Sun X; Huang H; Tan K; Zhao X; Li R; Jiang W; Sui Y; Chen X; Shen K; Zhang L; Ma J; Zhao K; Tang Y
Cancer Res; 2021 Jun; 81(11):3105-3120. PubMed ID: 33853831
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models.
Dermawan JK; Hitomi M; Silver DJ; Wu Q; Sandlesh P; Sloan AE; Purmal AA; Gurova KV; Rich JN; Lathia JD; Stark GR; Venere M
Cancer Res; 2016 Apr; 76(8):2432-42. PubMed ID: 26921329
[TBL] [Abstract][Full Text] [Related]
11. FACT subunit SUPT16H associates with BRD4 and contributes to silencing of interferon signaling.
Zhou D; Wu Z; Park JG; Fiches GN; Li TW; Ma Q; Huang H; Biswas A; Martinez-Sobrido L; Santoso NG; Zhu J
Nucleic Acids Res; 2022 Aug; 50(15):8700-8718. PubMed ID: 35904816
[TBL] [Abstract][Full Text] [Related]
12. Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Xiao L; Somers K; Murray J; Pandher R; Karsa M; Ronca E; Bongers A; Terry R; Ehteda A; Gamble LD; Issaeva N; Leonova KI; O'Connor A; Mayoh C; Venkat P; Quek H; Brand J; Kusuma FK; Pettitt JA; Mosmann E; Kearns A; Eden G; Alfred S; Allan S; Zhai L; Kamili A; Gifford AJ; Carter DR; Henderson MJ; Fletcher JI; Marshall G; Johnstone RW; Cesare AJ; Ziegler DS; Gudkov AV; Gurova KV; Norris MD; Haber M
Clin Cancer Res; 2021 Aug; 27(15):4338-4352. PubMed ID: 33994371
[TBL] [Abstract][Full Text] [Related]
13. The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy.
Lv Y; Du Y; Li K; Ma X; Wang J; Du T; Ma Y; Teng Y; Tang W; Ma R; Wu J; Wu J; Feng J
Cell Commun Signal; 2023 Jan; 21(1):16. PubMed ID: 36691066
[TBL] [Abstract][Full Text] [Related]
14. Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Burkhart C; Fleyshman D; Kohrn R; Commane M; Garrigan J; Kurbatov V; Toshkov I; Ramachandran R; Martello L; Gurova KV
Oncotarget; 2014 Nov; 5(22):11038-53. PubMed ID: 25402820
[TBL] [Abstract][Full Text] [Related]
15. Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms.
Jin MZ; Xia BR; Xu Y; Jin WL
Front Oncol; 2018; 8():598. PubMed ID: 30581774
[TBL] [Abstract][Full Text] [Related]
16. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice.
Koman IE; Commane M; Paszkiewicz G; Hoonjan B; Pal S; Safina A; Toshkov I; Purmal AA; Wang D; Liu S; Morrison C; Gudkov AV; Gurova KV
Cancer Prev Res (Phila); 2012 Aug; 5(8):1025-35. PubMed ID: 22689915
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of an anti-tumor immune response with "chromatin-damaging" therapy.
Chen M; Brackett CM; Burdelya LG; Punnanitinont A; Patnaik SK; Matsuzaki J; Odunsi AO; Gudkov AV; Singh AK; Repasky EA; Gurova KV
Cancer Immunol Immunother; 2021 Jul; 70(7):2073-2086. PubMed ID: 33439292
[TBL] [Abstract][Full Text] [Related]
18. Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression.
Shen J; Chen M; Lee D; Law CT; Wei L; Tsang FH; Chin DW; Cheng CL; Lee JM; Ng IO; Wong CC; Wong CM
Gut; 2020 Feb; 69(2):329-342. PubMed ID: 31439637
[TBL] [Abstract][Full Text] [Related]
19. CBL0137 activates ROS/BAX signaling to promote caspase-3/GSDME-dependent pyroptosis in ovarian cancer cells.
Yang C; Wang ZQ; Zhang ZC; Lou G; Jin WL
Biomed Pharmacother; 2023 May; 161():114529. PubMed ID: 37002567
[TBL] [Abstract][Full Text] [Related]
20. Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program.
Lock R; Carol H; Maris JM; Kolb EA; Gorlick R; Reynolds CP; Kang MH; Keir ST; Wu J; Purmal A; Gudkov A; Kurmashev D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27650817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
